These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

903 related articles for article (PubMed ID: 16203817)

  • 41. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
    Sievers EL; Larson RA; Stadtmauer EA; Estey E; Löwenberg B; Dombret H; Karanes C; Theobald M; Bennett JM; Sherman ML; Berger MS; Eten CB; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR;
    J Clin Oncol; 2001 Jul; 19(13):3244-54. PubMed ID: 11432892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
    Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
    Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibody therapy for acute myeloid leukemia.
    Mulford D
    Semin Hematol; 2008 Apr; 45(2):104-9. PubMed ID: 18381105
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin.
    Fernandez HF; Sun Z; Litzow MR; Luger SM; Paietta EM; Racevskis J; Dewald G; Ketterling RP; Rowe JM; Lazarus HM; Tallman MS
    Blood; 2011 May; 117(20):5306-13. PubMed ID: 21415269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
    Linenberger ML
    Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.
    Pollard JA; Alonzo TA; Loken M; Gerbing RB; Ho PA; Bernstein ID; Raimondi SC; Hirsch B; Franklin J; Walter RB; Gamis A; Meshinchi S
    Blood; 2012 Apr; 119(16):3705-11. PubMed ID: 22378848
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
    Versluis J; Hazenberg CL; Passweg JR; van Putten WL; Maertens J; Biemond BJ; Theobald M; Graux C; Kuball J; Schouten HC; Pabst T; Löwenberg B; Ossenkoppele G; Vellenga E; Cornelissen JJ;
    Lancet Haematol; 2015 Oct; 2(10):e427-36. PubMed ID: 26686044
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
    Stasi R
    Expert Opin Biol Ther; 2008 Apr; 8(4):527-40. PubMed ID: 18352855
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia.
    Reinhardt D; Diekamp S; Fleischhack G; Corbacioglu C; Jürgens H; Dworzak M; Kaspers G; Creutzig U; Zwaan CM
    Onkologie; 2004 Jun; 27(3):269-72. PubMed ID: 15249716
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse.
    Shannon-Dorcy K
    Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
    Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT
    Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070
    [No Abstract]   [Full Text] [Related]  

  • 53. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
    Tsimberidou A; Cortes J; Thomas D; Garcia-Manero G; Verstovsek S; Faderl S; Albitar M; Kantarjian H; Estey E; Giles FJ
    Leuk Res; 2003 Oct; 27(10):893-7. PubMed ID: 12860008
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.
    Chevallier P; Mahe B; Garand R; Talmant P; Harousseau JL; Delaunay J
    Int J Hematol; 2008 Sep; 88(2):209-211. PubMed ID: 18668307
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful outcome of allo-SCT in high-risk pediatric AML using chemotherapy-only conditioning and post transplant immunotherapy.
    Bonanomi S; Connor P; Webb D; Ancliff P; Amrolia P; Rao K; McCloskey D; Hemmatpour S; Goulden N; Veys P
    Bone Marrow Transplant; 2008 Aug; 42(4):253-7. PubMed ID: 18560412
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.
    Duong HK; Sekeres MA
    Clin Interv Aging; 2009; 4():197-205. PubMed ID: 19503782
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
    Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
    Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Reinduction therapy with gemtuzumab ozogamicin for relapsed or refractory CD33-positive acute myelogeneous leukemia].
    Shimokawa T; Kojima Y
    Gan To Kagaku Ryoho; 2008 Aug; 35(8):1427-30. PubMed ID: 18701865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.
    Taksin AL; Legrand O; Raffoux E; de Revel T; Thomas X; Contentin N; Bouabdallah R; Pautas C; Turlure P; Reman O; Gardin C; Varet B; de Botton S; Pousset F; Farhat H; Chevret S; Dombret H; Castaigne S
    Leukemia; 2007 Jan; 21(1):66-71. PubMed ID: 17051246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.
    Russell JA; Savoie ML; Balogh A; Turner AR; Larratt L; Chaudhry MA; Storek J; Bahlis NJ; Brown CB; Quinlan D; Geddes M; Stewart DA
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):814-21. PubMed ID: 17580259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.